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K+ channelThe present study investigated the mechanisms involved in the antinociception produced by the triterpene 3β,
6β, 16β-trihydroxylup-20(29)-ene (TTHL) in mice. TTHL administered by intra-gastric (i.g.) gavage inhibited
glutamate-induced nociceptionwith an ID50 of 19.0 (13.2–27.5)mg/kg. This action started 60 min (inhibition of:
59±6%) after i.g. administration and remained signiﬁcant up to 6 h (inhibition of 37±6%). Moreover, TTHL
inhibited both phases of formalin induced pain. The antinociception of TTHL was reversed by the pre-
administration of naloxone (1 mg/kg; non-selective opioid receptor antagonist), CTOP (1 mg/kg; selective μ-
opioid receptor antagonist), nor-binaltorphimine (1 mg/kg; selective κ-opioid receptor antagonist), naltrindol
(3 mg/kg; selective δ-opioid receptor antagonist), p-chlorophenylalanine methyl ester (100 mg/kg for 4
consecutivedays; inhibitorof serotonin synthesis),WAY100635(0.5 mg/kg; selective5-HT1A receptor antagonist)
and ketanserin (0.3 mg/kg; selective 5-HT2A receptor antagonist) but not by L-arginine (600 mg/kg; nitric oxide
precursor) or ondansetron (0.5 mg/kg; 5-HT3 receptor antagonist). Furthermore, the TTHL antinociception was
prevented by intrathecal (i.t.) pre-treatment with pertussis toxin (0.5 μg/site; inactivator of Gi/o protein),
charybdotoxin (250 pg/site; blocker of large-conductance calcium-gated K+ channels), tetraethylammonium
(1 μg/site; blocker of voltage-gated K+ channels) and glibenclamide (80 μg/site; blocker of ATP-gated K+
channels) but not by apamin (50 ng/site; blocker of small-conductance calcium-gated K+ channels). The
antinociception of TTHL was not it associatedwith locomotor impairment or sedation. These results showed that
TTHL presented a pronounced antinociceptive effect, which is dependent on opioid and serotonergic systems, Gi/o
protein activation and the opening of speciﬁc K+ channels.isiológicas, Centro de Ciências
mpus Universitário Trindade,
352; fax: +55 48 3721 9672.
).
vier OA license.© 2010 Elsevier B.V. Open access under the Elsevier OA license.1. Introduction
The sensation of pain is known to be modiﬁed by endogenous pain
inhibitory systems, predominantly through descending noradrenaline,
serotonin, andendogenous opioids suchasβ-endorphin anddynorphin.
The activation of the descending systems markedly modiﬁes not only
the release of glutamate from the primary afferent or interneurons but
also the release of GABA and glycine (Yoshimura and Furue, 2006).
Evidence has shown that the opening of some K+ channels plays
an important role in the antinociception induced by agonists of many
G-protein-coupled receptors (i.e., α2-adrenoceptors, opioid, GABAB,
muscarinic M2, adenosine A1, serotonin 5-HT1A and cannabinoid
receptors), as well as by other antinociceptive drugs (nonsteroidal
anti-inﬂammatory drugs and tricyclic antidepressants) and natural
products (Ocaña et al., 2004).In recent years, the pharmaceutical industry has shown considerable
interest in new drugs originating from natural sources. In this regard,
species of Combretum are used in traditional medicine to treat various
diseases, such aspain. The genusCombretumbelongs to theCombretacea
family, and several species arewidely distributedaroundAfrica (McGaw
et al., 2001). In north and northeastern Brazil, species of this genus are
also found, namely Combretum leprosum Mart., popularly known as
mofumbo, cipoaba or mufumbo. Infusions prepared with the aerial
(stems, leaves andﬂowers)parts and roots ofC. leprosumare used in folk
medicine to heal wounds, in the treatment of hemorrhages or as a
sedative (Facundo et al., 2005; Lira et al., 2002). Phytochemical studies
performed by Facundo et al. (1993) have revealed some compounds
found in this plant, such as ﬂavonols and triterpenes.
We reported that the ethanolic extract obtained from the ﬂowers
of C. leprosum evoked dose-related antinociception in several models
of chemical and thermal pain through mechanisms that involve an
interaction with opioid and serotonergic (i.e., through 5-HT1A/1B and
5-HT2A receptors) systems (Pietrovski et al., 2006). Additionally, it
was demonstrated that the pentacyclic triterpene 3β, 6β, 16β-
trihydroxylup-20(29)-ene (TTHL) obtained from this plant presents
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(Longhi-Balbinot et al., 2009).
However, despite experimental data, themechanism throughwhich
the triterpene evokes systemic antinociception in rodents still remains
elusive. In this regard, the aim of the present study was to evaluate the
effect of 3β, 6β, 16β-trihydroxylup-20(29)-ene (TTHL) on pathways of
pain transmission, other than those described previously for TTHL.
Therefore, we investigated the endogenous pain inhibitory systems
such as endogenous opioids and serotonin (5-HT), as well as inhibitory
signaling pathways, including protein Gi/o activation and the opening of
potassium channels in mice.
2. Materials and methods
2.1. Animals
All experiments were performed after approval of the protocol by the
Ethics Committee for Animal Research of the Federal University of Santa
Catarina and were carried out in accordance with the current guidelines
for the care of laboratory animals and the ethical guidelines for
investigations of experimental pain in conscious animals (Zimmermann,
1983). Experiments were conducted using male Swiss mice (25–35 g)
obtained from the Federal University of Santa Catarina's animal facility
that were housed at 22±2 °C under a 12-h light/12-h dark cycle (lights
on at 06:00) with access to food and water ad libitum. The mice were
acclimatized to the laboratory for at least 1 hbefore testing andwereused
only once throughout the experiments.
2.2. Glutamate-induced nociception
The procedure used was similar to that described previously (Meotti
et al., 2009). First, animals were treated with TTHL (3–100 mg/kg)
administered by intra-gastric (i.g.) gavage 1 hbefore glutamate injection.
Control animals received a similar volume of vehicle (10 ml/kg). Then, a
volume of 20 μl of glutamate (20 μmol/paw), made up in sterile saline
solution with the pH adjusted to 7.0 with NaOH, was injected
intraplantarly (i.pl.) under the ventral surface of the right hindpaw.
Animals were observed individually for 15 min following glutamate
injection. The amount of time they spent licking the injected paw was
recorded with a chronometer and was considered indicative of
nociception. In separate series of experiments, we investigated the time
course of the antinociceptive effect of TTHL (30 mg/kg) given orally at
time points 1, 2, 4, 6, 8 and 10 h before glutamate administration. Control
animals received a similar volume of vehicle (10 ml/kg) by intra-gastric
(i.g.) gavage route and were observed over the same intervals of time.
2.3. Formalin-induced nociception
The procedure used was essentially the same as that previously
described (Hunskaar et al., 1985; Tjølsen et al., 1992). Animals
received 20 μl of a 2.5% formalin solution (0.92% formaldehyde in
saline) in the ventral surface of the right hind paw (i.pl.). Animals
were observed from 0 to 5 min (neurogenic phase) and from 15 to
30 min (inﬂammatory phase) and the time that they spent licking the
injected paw was recorded and considered as indicative of nocicep-
tion. Animals were pre-treated with TTHL (10–300 mg/kg, i.g.) 1 h
beforehand. Control animals received the same volume of vehicle
(10 ml/kg, i.g.).
2.4. Analysis of possible mechanism of action of TTHL
The mechanisms by which TTHL (30 mg/kg), administered
systemically, evokes antinociception were evaluated utilizing the
nociception model induced by glutamate. The doses of all substances
employed were chosen based on literature data or were selected from
preliminary experiments conducted in our laboratory.2.4.1. Involvement of opioid system
To assess the participation of the opioid system in the antinoci-
ceptive effect of TTHL, micewere pre-treatedwith naloxone (1 mg/kg,
intraperitoneally [i.p.], a non-selective opioid receptor antagonist),
CTOP (1 mg/kg, subcutaneously [s.c.], a selective μ-opioid receptor
antagonist), nor-binaltorphimine (1 mg/kg, i.p., a selective κ-opioid
receptor antagonist) or naltrindol (3 mg/kg, s.c., a selective δ-opioid
receptor antagonist). After 20 min, the animals received TTHL
(30 mg/kg, i.g.), morphine (2.5 mg/kg, s.c.) or vehicle (10 ml/kg, i.g.).
Another group of mice was pre-treated with vehicle and after 20 min,
received TTHL,morphine or vehicle. Thenociceptive response to the i.pl.
glutamate injection was recorded 60 min after the administration of
TTHL or vehicle and 30 min after the administration of morphine. The
doses and scheme of treatment for naltrindole and nor-binaltorphimine
were selected based on literature data (Backhouse et al., 2008; Jinsmaa
et al., 2006). CTOP was injected subcutaneously based on data showing
that it produced effects as a selective μ-opioid antagonist when injected
systemically (Banach et al., 2006; Catheline et al., 1999; Varlinskaya and
Spear, 2009).
2.4.2. Involvement of serotonergic system
To investigate the possible involvement of endogenous serotonin
on the antinociceptive effect of TTHL, animals were pre-treated with
p-chlorophenylalanine methyl ester (PCPA, 100 mg/kg, i.p., an
inhibitor of serotonin synthesis) or vehicle, once a day, for 4
consecutive days. Twenty minutes after the last administration of
PCPA,mice received TTHL (30 mg/kg, i.g.), morphine (2.5 mg/kg, s.c.) or
vehicle (10 ml/kg, i.g.). The nociceptive response to i.pl. glutamate was
recorded 30 and 60 min after morphine, TTHL or vehicle
injection, respectively. In the next series of experiments, we evaluated
the contribution of the different subtypes of serotonin (5-HT) receptors.
Thus, the animals were pre-treated with WAY100635 (0.5 mg/kg, s.c.,
a selective 5-HT1A receptor antagonist), ketanserin (1 mg/kg, i.p.,
a selective 5-HT2A receptor antagonist), ondansetron (0.5 mg/kg, i.p.,
a 5-HT3 receptor antagonist) or vehicle (10 ml/kg, i.p.). Twenty
minutes after drug administration, the animals were treated with
TTHL (30 mg/kg, i.g.) or vehicle (10 ml/kg, i.g.), and as positive controls,
buspirone (5 mg/kg, i.p., a 5-HT1A receptor agonist), DOI (1 mg/kg, i.p., a
5-HT2A/2C receptor agonist) or agmatine (3 mg/kg, i.p., which in
previous studies in our laboratory had its antinociceptive effects
reversed by ondansetron) (Luiz et al., 2007; Santos et al., 2005) was
used. Furthermore, a group of mice was pre-treated with vehicle and
after 30 min, received TTHL or vehicle. The nociceptive response to i.pl.
glutamate injection was recorded 60 min after the administration of
TTHL or vehicle and 30min after the administration of agonists.
2.4.3. Involvement of L-arginine–nitric oxide pathway
To investigate the role playedby theL-arginine–nitric oxidepathway
in the antinociception caused by TTHL, mice were pre-treated with L-
arginine (600 mg/kg, i.p.; a nitric oxide precursor). After 20 min, the
mice received TTHL (30 mg/kg, i.g.), L-NAME (20 mg/kg, i.p.; a nitric
oxide synthase inhibitor) or vehicle (10 ml/kg, i.g.) (Maia et al., 2006;
Santos et al., 2005). Another group ofmicewas pre-treatedwith vehicle
and after 30 min, received TTHL, L-NAME or vehicle. The nociceptive
response to i.pl. glutamate injection was recorded 60 min after the
administration of TTHLor vehicle and 30 min after the administration of
L-NAME.
2.4.4. Participation of Gi/o protein
To determine the involvement of Gi/o protein in the antinociceptive
action of TTHL, mice were pre-treated intrathecally (i.t.) with pertussis
toxin (0.5 μg/site), an inactivator of Gi/o protein. A control group was
pre-treated with vehicle (5 μl/i.t.). The intrathecal injection was
performed as previously described by Hylden and Wilcox (1980).
Animalsweremanually restrained, and a 30-gaugeneedle connected by
polyethylene tubing to a 25 μL Hamilton gas-tight syringe (Hamilton,
Fig. 1. Dose–response (panel A, open bars) and time-course (panel B, open circle) of the
antinociceptive effect of TTHL given by intra-gastric (i.g.) gavage against glutamate-
induced nociception inmice. Each group represents themean of 8 animals and the error
lines indicate the S.E.M. The control group (C, grey bar or closed circle) indicates the
mice treated by intra-gastric (i.g.) gavage with vehicle (10 ml/kg) before glutamate
(20 μmol/paw). The symbols ⁎Pb0.05, ⁎⁎Pb0.01 and ⁎⁎⁎Pb0.001 denote the signiﬁ-
cance level when compared to the control group. One-way ANOVA followed by the
Newman–Keuls test.
34 D.T. Longhi-Balbinot et al. / European Journal of Pharmacology 653 (2011) 32–40Birmingham, UK), was inserted through the skin and between the
vertebras into the subdural space of the L5–L6 spinal segments. The tail
reﬂex movement was considered as indicative of success of adminis-
tration and the injections were given over a period of 5 s. The
experiment was carried out as described by Sánchez-Blázquez and
Garzón (1991) and Meotti et al. (2007). Seven days after treatment of
animalswith pertussis toxin or vehicle,mice received vehicle (10 ml/kg,
i.g.), TTHL (30 mg/kg, i.g.) ormorphine (2.5 mg/kg, s.c.). The nociceptive
response to i.pl. glutamate injection was recorded 60 min after the
administration of TTHLor vehicle and 30min after the administration of
morphine.
2.4.5. Involvement of K+ channels
We next investigated the involvement of K+ channels on the
antinociceptive action of TTHL. Mice were pre-treated intrathecally,
as described earlier, with K+ channel blockers tetraethylammonium
(1 μg/site, i.t.; a blocker of voltage-gated K+ channels), apamin
(50 ng/site, i.t.; a blocker of small (or low)-conductance calcium-
gated K+ channels), charybdotoxin (250 pg/site, i.t.; a blocker of large
(or fast)-conductance calcium-gated K+ channels) or glibenclamide
(80 μg/site, i.t.; a blocker of ATP-gated K+ channels), and after 15 min,
they received TTHL (30 mg/kg, i.g.), morphine (2.5 mg/kg, s.c.) or
vehicle (10 ml/kg, i.g.) (Aronson, 1992; Meotti et al., 2007; Santos
et al., 1999; Strong, 1990; Welch and Dunlow, 1993). Another group
of mice was pre-treated with vehicle and after 15 min, they received
TTHL, morphine or vehicle. The nociceptive response to i.pl. glutamate
injection was recorded 60 min after the administration of TTHL or
vehicle and 30 min after the administration of morphine.
2.5. Measurement of locomotor activity
To evaluate the effect of TTHL on spontaneous locomotor activity,
mice were submitted to the open ﬁeld test (Rodrigues et al., 2002).
The open-ﬁeld apparatus consisted of a wooden box measuring
40×60×50 cm. The ﬂoor of the arena was divided into 12 equal
squares, and the number of squares crossed by the animal with all
paws was counted in a 6 min session. Mice were treated by intra-
gastric gavage with TTHL (30 and 100 mg/kg) or vehicle (10 ml/kg)
60 min beforehand.
2.6. Drugs
The following substances were employed: formalin and morphine
hydrochloride from Merck (Darmstadt, Germany), L-glutamic acid
hydrochloride (glutamate), naloxone hydrochloride, (±)-2,5-
Dimethoxy-4-iodoamphetamine hydrochloride ((±)-DOI), agmatine
sulphate, buspirone hydrochloride, L-arginine, Nω-nitro-L-arginine
methyl ester hydrochloride (L-NAME), p-chlorophenyl methyl ester
hydrochloride (PCPA), N-[2-[4-(2-Methoxyphenyl)-1-piperazinyl]
ethyl]-N-2-pyridinylcyclohexanecarboxamide (WAY 100635), per-
tussis toxin, charybdotoxin, tetraethylammonium and apamin from
Sigma Chemical Co. (St. Louis, USA), naloxone hydrochloride,
naltrindol hydrochloride, D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-
NH2 (CTOP), nor-binaltorphimine hydrochloride, glibenclamide and
ketanserin tartarate from Tocris Cookson Inc. (Ellisville, USA) and
ondansetron hydrochloride from Cristália (São Paulo, Brazil). All
drugs were dissolved in saline solution (0.9%), except TTHL and
glibenclamide, which were dissolved in saline plus DMSO/Tween 80
or saline plus ethanol/Tween 80, respectively. The ﬁnal concentration
of DMSO, Tween 80 and ethanol did not exceed 10% and did not cause
any effect per se. The triterpene 3β, 6β, 16β-trihydroxylup-20(29)-
ene was isolated from the ﬂowers of C. leprosum at the Department of
Organic Chemistry, Universidade Federal do Ceará, Brazil as previ-
ously described and its degree of purity was N98%. (Facundo et al.,
1993).2.7. Statistical analysis
Data are presented asmeans±standard error of themean (S.E.M.),
except the ID50 values (i.e., the dose of triterpene that reduced the
agonists-induced nociceptive response by 50% relative to control
value), which are reported as geometric means accompanied by their
respective 95% conﬁdence limits. The ID50 value was determined by
non-linear regression from individual experiments (GraphPad soft-
ware, San Diego, CA, USA). Comparisons between experimental and
control groups were performed by one-way (effect of TTHL in the
glutamate- and formalin-induced nociception and open-ﬁeld behav-
ior) or two-way (experiments dealing with the involvement of the
opioidergic and serotonergic system, L-arginine–nitric oxide pathway,
participation of Gi/o protein, ATP-dependent, voltage- and large (fast)-
conductance Ca2 +-gated K+ channels in the effect of TTHL in the
glutamate test) Analysis of Variance (ANOVA), followed by Newman
Keul's test or Tukey's HSD test when appropriate. P values less than
0.05 were considered as indicative of signiﬁcance.3. Results
3.1. Glutamate-induced nociception
The results of Fig. 1A show that TTHL (3–100 mg/kg) administered
by intra-gastric (i.g.) gavage caused a signiﬁcant inhibition of
glutamate-induced nociception when compared to the control group.
The calculated mean ID50 was 19.0 (13.2–27.5) mg/kg, and the
inhibition was 56±3% at a dose of 30 mg/kg. When glutamate was
administered at different time points after TTHL treatment, we veriﬁed
that TTHL had a peak response after 1 h (inhibition of 59±6%) that
lasted up to 6 h (inhibition of 37±6%, Fig. 1B).
Fig. 2. Effect of TTHL (open bars) administered by intra-gastric (i.g.) gavage against
formalin-induced nociception (ﬁrst phase, panel A, and second phase, panel B) in mice.
Each group represents the mean of 6 animals and the error lines indicate the S.E.M. The
control group (C, grey bars), indicates the mice treated by intra-gastric (i.g.) gavage
with vehicle (10 ml/kg) before formalin. The symbols ⁎Pb0.05, ⁎⁎Pb0.01 and
⁎⁎⁎Pb0.001 denote the signiﬁcance level when compared to the control group. One-
way ANOVA followed by the Newman–Keuls test.
35D.T. Longhi-Balbinot et al. / European Journal of Pharmacology 653 (2011) 32–403.2. Formalin-induced nociception
The results depicted inFig. 2AandB show that TTHL(10–300 mg/kg)
administered by intra-gastric (i.g.) gavage caused signiﬁcant inhibition
of both neurogenic (0 to 5 min) and inﬂammatory phases (15 to
30 min)of formalin-induced licking. The calculatedmean ID50 values for
these effects were 108.0 (72.6–160.8) mg/kg and~30 mg/kg and theFig. 3. Effect of pre-treatment with naloxone (1 mg/kg, i.p., panel A), CTOP (1 mg/kg, s.c., panel
the antinociceptive effect of TTHL (30 mg/kg, i.g.) against glutamate-induced nociception inmi
the absence (grey bars) or presence (open bars) of opioid antagonists. The symbols denote sign
alone); ##Pb0.01 and ###Pb0.001 compared to the TTHL group Two-way ANOVA followed byinhibitions observed were 63±5% and 51±9% at a dose of 100 mg/kg
and 30 mg/kg, for the ﬁrst and second phases, respectively.
3.3. Analysis of possible mechanism of action of TTHL
3.3.1. Involvement of opioidergic system in the antinociceptive effect of
TTHL
The results depicted in Fig. 3A show the effect of naloxone (1 mg/kg,
i.p.; a non-selective opioid receptor antagonist) on the antinociceptive
effect promoted by TTHL (30 mg/kg, i.g.) against glutamate-induced
nociception. The two-way ANOVA revealed signiﬁcant main effects of
naloxone pre-treatment [F(1,16)=6.81; Pb0.05] and TTHL [F(1,16)=
16.09; Pb0.001], and a naloxone pre-treatment×TTHL interaction
[F(1,16)=7.10; Pb0.05]. Post hoc analyses (Tukey HSD) indicated that
the pre-administration of naloxone signiﬁcantly prevented the anti-
nociceptive effect elicited by TTHL (Pb0.01).
Fig. 3B shows the effect of the pre-administration of CTOP (1 mg/kg,
s.c.; a selective μ-opioid receptor antagonist) on the antinociceptive
effect promoted by TTHL (30 mg/kg, i.g.) against glutamate-induced
nociception. The two-way ANOVA revealed signiﬁcant main effects of
CTOP pre-treatment [F(1,32)=24.72; Pb0.001] and TTHL [F(1,32)=
99.24; Pb0.001], and a CTOPpre-treatment×TTHL interaction [F(1,32)=
38.27; Pb0.001]. Post hoc analyses indicated that the pre-treatment of
mice with CTOP signiﬁcantly reversed the antinociceptive effect evoked
by TTHL (Pb0.001).
Fig. 3C shows the effect of pre-administration of nor-binaltorphimine
(1 mg/kg, i.p.; a selective κ-opioid receptor antagonist) on the
antinociceptive effect caused by TTHL (30 mg/kg, i.g.) against
glutamate-induced nociception. The two-way ANOVA revealed signi-
ﬁcantmain effects of nor-binaltorphimine pre-treatment [F(1,32)=17.0;
Pb0.001] and TTHL F(1,32)=108.51; Pb0.001], and a nor-binaltorphi-
mine pre-treatment×TTHL interaction [F(1,32)=23.10; Pb0.001]. Post
hocanalyses indicated that thepre-administrationofnor-binaltorphimine
prevented the antinociceptive effect elicited by TTHL (Pb0.01).
Fig. 3D shows the effect of the pre-treatment of mice with
naltrindole (3 mg/kg, s.c.; a selective δ-opioid receptor antagonist) on
the antinociceptive effect promoted by TTHL (30 mg/kg, i.g.) against
glutamate-induced nociception. The two-way ANOVA revealedB), nor-binaltorphimine (1 mg/kg, i.p., panel C) and naltrindole (3 mg/kg, s.c., panel D) on
ce. Each column represents themean of 9 animals and the error lines indicate the S.E.M. in
iﬁcance levels: ⁎⁎⁎Pb0.001 compared to the control group (animals injected with vehicle
the Tukey HSD test.
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Pb0.05] and TTHL [F(1,32)=47.05; Pb0.001], and a naltrindole pre-
treatment×TTHL interaction [F(1,32)=34.09; Pb0.001]. Post hoc
analyses indicated that the pre-administration of naltrindole pre-
vented the antinociceptive effect elicited by TTHL (Pb0.001).
The pre-administration of naloxone, CTOP, nor-binaltorphimine or
naltrindole reversed the antinociceptive effect caused by morphine
(2.5 mg/kg, s.c., used as a positive control) [F(1,20)=24.6; Pb0.001],
[F(1,32)=170.97; Pb0.001], [F(1,32)=254.32; Pb0.01] and [F(1,32)=
80.86; Pb0.01] respectively,when analyzed against glutamate test (data
not shown).
3.3.2. Involvement of serotonergic system in the antinociception afforded
by TTHL
Fig. 4A shows the effect of the pre-administration of PCPA (100 mg/kg,
i.p., an inhibitor of serotonin synthesis, for 4 consecutive days) on the
antinociception promoted by TTHL (30 mg/kg, i.g.) against glutamate-
induced nociception. The Two-way ANOVA revealed signiﬁcant
main effects of PCPA pre-treatment [F(1,28)=5.93; Pb0.05] and TTHL
[F(1,28)=12.22; Pb0.001], and a PCPA pre-treatment×TTHL interaction
[F(1,28)=18.12; Pb0.001]. Post hoc analyses indicated that the pre-
treatment of mice with PCPA signiﬁcantly reversed the antinociceptive
effect elicited by TTHL (Pb0.001).
Fig. 4B shows the effect of the pre-treatment of mice with
WAY100635 (0.5 mg/kg, s.c.; a selective 5-HT1A receptor antagonist)
on the antinociceptive effect promoted by TTHL (30 mg/kg, i.g.) against
glutamate-induced nociception. The two-way ANOVA revealed signif-
icant main effects of WAY100635 pre-treatment [F(1,24)=5.62;
Pb0.05] and TTHL [F(1,24)=64.96; Pb0.001], and a WAY100635 pre-
treatment×TTHL interaction [F(1,24)=16.45; Pb0.001]. Post hoc
analyses indicated that the pre-treatment of mice with WAY100635
prevented the antinociceptive effect elicited by TTHL (Pb0.001).
Fig. 4C shows the effect of the pre-treatment of mice with ketanserin
(0.3 mg/kg, i.p.; a selective 5-HT2A receptor antagonist) on the anti-
nociceptive effect promoted by TTHL (30 mg/kg, i.g.) against glutamate-
induced nociception. The Two-way ANOVA revealed signiﬁcant
main effects of ketanserin pre-treatment [F(1,20)=7.80; Pb0.05] and
TTHL F(1,20)=25.82; Pb0.001], and a ketanserin pre-treatment×TTHLFig. 4. Effect of pre-treatment with PCPA (100 mg/kg, i.p., for 4 consecutive days, panel A), WA
(0.5 mg/kg, i.p., panel D) on the antinociceptive effect of TTHL (30 mg/kg, i.g.) against glutamate
lines indicate the S.E.M. in theabsence (greybars) orpresence (openbars) of PCPAor serotonerg
group (animals injected with vehicle alone); #P b0.05, ##P b0.01 and ###P b0.001 compared tointeraction [F(1,20)=7.07; Pb0.05]. Post hoc analyses indicated that the
pre-administration of ketanserin prevented the antinociceptive effect
elicited by TTHL (Pb0.01).
Fig. 4D shows the effect of the pre-administration of ondansetron
(0.5 mg/kg, i.p.; a selective 5-HT3 receptor antagonist) on the antinoci-
ceptive effect promoted by TTHL (30 mg/kg, i.g.) against glutamate-
induced nociception. The two-way ANOVA revealed signiﬁcant differ-
ences of TTHL treatment [F(1,24)=56.93, Pb0.001], but not of
ondansetron pre-treatment [F(1,24)=0.56, P=0.45] and ondansetron
pre-treatment×TTHL treatment interaction [F(1,24)=1.98, P=0.17].
The pretreatment of mice with PCPA (100 mg/kg, i.p. for 4
consecutive days) reversed the antinociceptive effect caused by
morphine (2.5 mg/kg, s.c., used as a positive control) [F(1,28)=74.84;
Pb0.001] when analyzed against glutamate test (data not shown).
Furthermore, WAY100635 (a selective 5-HT1A receptor antagonist),
ketanserin (a selective 5-HT2A receptor antagonist) and ondansetron
(a selective 5-HT3 receptor antagonist), prevented the antinociceptive
effect of their respective agonists, used as a positive control, buspirone
(5 mg/kg, i.p.; a 5-HT1A receptor agonist) [F(1,24)=51.60; Pb0.001],
DOI (1 mg/kg, i.p.; a 5-HT2A/2C receptor agonist) [F(1,20)=17.89;
Pb0.001] and agmatine (3 mg/kg, i.p.) [F(1,24)=15.52; Pb0.001]when
analyzed against glutamate test, respectively (data not shown).3.3.3. Involvement of L-arginine–nitric oxide pathway
The results in Fig. 5 illustrate the involvement of L-arginine–nitric
oxide pathway in the antinociceptive effect of TTHL (30 mg/kg, i.g.)
in the glutamate test. Fig. 5 shows that the pre-treatment of mice with
L-arginine (600 mg/kg, i.p.; a nitric oxide precursor) was not able to
prevent the antinociceptive effect of TTHL in the glutamate test.
The two-way ANOVA revealed signiﬁcant differences of TTHL treat-
ment [F(1,24)=73.86; Pb0.001], but not of L-arginine pre-treatment
[F(1,24)=1.85; P=0.18] and L-argininepre-treatment×TTHL treatment
interaction [F(1,24)=0.24, P=0.62].
The pre-administration of L-arginine, given 20 min beforehand,
completely reversed the antinociceptive effect caused by L-NAME
(20 mg/kg, i.p.; a nitric oxide synthase inhibitor, used as a positive
control) [F(1,24)=32.60; Pb0.001] (data not shown).Y 100635 (0.5 mg/kg, s.c., panel B), ketanserin (0.3 mg/kg, i.p., panel C) and ondansetron
-induced nociception inmice. Each column represents themean of 7 animals and the error
ic antagonists. The symbolsdenote signiﬁcance levels: ⁎⁎⁎Pb0.001 compared to thecontrol
the TTHL group. Two-way ANOVA followed by the Tukey HSD test.
Fig. 5. Effect of pre-treatment with L-arginine (600 mg/kg, i.p.) on the antinociceptive
effect of TTHL (30 mg/kg, i.g.) against glutamate-induced nociception in mice. Each
column represents the mean of 8 animals and the error lines indicate the S.E.M. in the
absence (grey bars) or presence (open bars) of L-arginine. The symbols denote
signiﬁcance levels: ⁎⁎⁎Pb0.001 compared to the control group (animals injected with
vehicle alone). Two-way ANOVA followed by the Tukey HSD test.
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Fig. 6 shows the effect of the pre-administration of pertussis toxin
(0.5 μg/site, i.t. for 7 consecutive days) on the antinociceptive effect
promoted by TTHL (30 mg/kg, i.g.) against glutamate-induced nocicep-
tion. The two-way ANOVA revealed signiﬁcant main effects of pertussis
toxin pre-treatment [F(1,36)=41.01; Pb0.001] and TTHL [F(1,36)=
46.70; Pb0.001], and a pertussis toxin pre-treatment×TTHL interaction
[F(1,36)=10.22; Pb0.001]. Post hoc analyses indicated that the pre-
treatment of mice with pertussis toxin completely abrogated the
antinociceptive effect elicited by TTHL (Pb0.001).
The pre-treatment of mice with pertussis toxin (0.5 μg/site, i.t. for 7
consecutive days) completely reversed the antinociceptive effect caused
bymorphine (2.5 mg/kg, s.c., used as a positive control) [F(1,36)=52.33;
Pb0.001] (data not shown).
3.3.5. Involvement of ATP-dependent, voltage- and large (fast)-
conductance Ca2+-gated K+ channels in the antinociceptive effect of TTHL
Fig. 7A shows the effect of the intrathecal pre-treatment ofmicewith
tetraethylammonium (1 μg/site, i.t.; a blocker of voltage-gated K+
channels) on the antinociception promoted by TTHL (30 mg/kg, i.g.)
against glutamate test. The two-way ANOVA revealed signiﬁcant main
effects of tetraethylammonium pre-treatment [F(1,28)=9.07;
Pb0.001] and TTHL [F(1,28)=12.92; Pb0.001], and a tetraethylammo-
nium pre-treatment×TTHL interaction [F(1,28)=7.61; Pb0.05]. Post
hoc analyses indicated that the pre-administration of tetraethylammo-
nium signiﬁcantly reversed the antinociceptive effect elicited by TTHL
(Pb0.001).
Fig. 7B shows that the intrathecal pre-administration of apamin
(50 ng/site, i.t.; a blocker of small (or low)-conductance calcium-
gated K+ channels) was not able to reverse the antinociceptive effect
of TTHL in the glutamate test. The two-way ANOVA revealedFig. 6. Effect of pre-treatment (prior seven days) with pertussis toxin (PTX) (0.5 μg/site, i.t.)
on the antinociceptive effect of TTHL (30mg/kg, i.g.) against glutamate-induced nociception
inmice. Eachcolumnrepresents themeanof10animals and theerror lines indicate theS.E.M.
in the absence (grey bars) or presence (open bars) of pertussis toxin. The symbols denote
signiﬁcance levels:⁎⁎⁎Pb0.001compared to thecontrol group (animals injectedwithvehicle
alone); ###Pb0.001 compared to the TTHL group. Two-way ANOVA followed by the Tukey
HSD test.signiﬁcant differences of TTHL treatment [F(1,24)=23.04; Pb0.001],
but not of apamin pre-treatment [F(1,24)=0.02; P=0.88] and
apamin pre-treatment×TTHL treatment interaction [F(1,24)=2.43;
P=0.13].
Fig. 7C shows the effect of the intrathecal pre-treatment ofmicewith
charybdotoxin (250 pg/site, i.t.; a blocker of large (or fast)-conductance
calcium-gated K+ channels) on the antinociception promoted by TTHL
(30 mg/kg, i.g.) against glutamate test. The two-way ANOVA revealed
signiﬁcantmain effects of charybdotoxinpre-treatment [F(1,28)=4,57;
Pb0.05] and TTHL [F(1,28)=14.89; Pb0.001], and a charybdotoxin pre-
treatment×TTHL interaction [F(1,28)=10.37; Pb0.05]. Post hoc anal-
yses indicated that the pre-administration of charybdotoxin prevented
the antinociceptive effect elicited by TTHL (Pb0.01).
Fig. 7D shows the effect of intrathecal pre-administration of
glibenclamide (80 μg/site, i.t.; a blocker of ATP-gated K+ channels) on
the antinociception promoted by TTHL (30 mg/kg, i.g.) against
glutamate test. The two-way ANOVA revealed signiﬁcant main effects
of glibenclamide pre-treatment [F(1,24)=30.83; Pb0.001] and TTHL
[F(1,24)=10.88; Pb0.001], and a glibenclamide pretreatment×TTHL
interaction [F(1,24)=26.83; Pb0.001]. Post hoc analyses indicated
that the pre-treatment of mice with glibenclamide prevented the
antinociceptive effect elicited by TTHL (Pb0.001).
The pre-administration of tetraethylammonium, apamin, charybdo-
toxin or glibenclamide reversed the antinociceptive effect caused by
morphine (2.5 mg/kg, s.c., used as a positive control) [F(1,28)=28.36;
Pb0.001], [F(1,24)=27.43; Pb0.001], [F(1,28)=45.07; Pb0.001] and
[F(1,24)=136.27; Pb0.001] respectively, when analyzed against
glutamate test (data not shown).
It is important to point out, that the pre-administration of all
antagonists/blockers employed did not produce any effect per se on
the glutamate-induced nociception (Figs. 3, 4, 5, 6 and 7).
3.4. Effect of TTHL on the locomotor activity (open-ﬁeld test)
TTHL (30 and 100 mg/kg), given 60 min beforehand, did not affect
the locomotor activity in the open-ﬁeld test when compared to mice
that received vehicle. The means±S.E.M. of crossing numbers were
96.8±8.0 for vehicle, 111.0±9.0 for TTHL 30 mg/kg, 104.8±6.5 for
TTHL 100 mg/kg.
4. Discussion
In the present work, we conﬁrm and largely extend previous data
from the literature and demonstrate that the systemic (intra-gastric
gavage) administration of TTHL, a pentacyclic triterpene isolated from
C. leprosum, signiﬁcantly inhibited the nociception induced by
peripherally (intraplantar)-injected glutamate that lasts up to 6 h
after treatment.
Studies in both humans (Gazerani et al., 2006; Nordlind et al.,
1993; Warncke et al., 1997) and laboratory animals (Cairns et al.,
1998; Davidson et al., 1997; Davidson and Carlton, 1998) have shown
that excitatory amino acids, such as glutamate, in the peripheral
endings of small diameter afferent ﬁbers might contribute to the
development and/or maintenance of pain. It has been demonstrated
that intraplantar (i.pl.) injection of L-glutamate into the hind paw
evokes hyperalgesia in rats (Carlton et al., 1995). Furthermore, Beirith
et al. (2002) showed that nociception caused by i.pl. glutamate seems
to involve peripheral, spinal and supra-spinal sites, and that its action
is mediated by NMDA and non-NMDA receptors, as well as by nitric
oxide (NO) release. Thus, the suppression of glutamate-induced
nociception by TTHL can be associated with its interaction with the
glutamatergic system or inhibition of NO production (Beirith et al.,
2002; Ferreira et al., 1999).
Another interesting ﬁnding of the present study was the demon-
stration that TTHL caused signiﬁcant antinociception when adminis-
tered orally against both neurogenic (early phase) and inﬂammatory
Fig. 7. Effect of i.t. pre-treatment with tetraethylammonium (1 μg/site, panel A), apamin (50 ng/site, panel B), charybdotoxin (250 pg/site, panel C) and glibenclamide (80 μg/site,
panel D) on the antinociceptive effect of TTHL (30 mg/kg, i.g.) against glutamate-induced nociception in mice. Each column represents the mean of 9 animals and the error lines
indicate the S.E.M. in the absence (grey bars) or presence (open bars) of K+ channel blockers. The symbols denote signiﬁcance levels: ⁎⁎⁎Pb0.001 compared to the control group
(animals injected with vehicle alone); ##Pb0.01 and ###Pb0.001 compared to the TTHL group. Two-way ANOVA followed by the Tukey HSD test.
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Furthermore, it has been reported that several drugs that antagonize
ionotropic and metabotropic glutamate receptors (Bhave et al., 2001;
Coderre et al., 1990; Fisher and Coderre, 1996; Yoon et al., 2006)
produce signiﬁcant antinociceptive action on formalin-induced noci-
ceptive behavior. However, these drugs produced signiﬁcant distur-
bances in locomotor activity (Parsons, 2001; Pietraszek et al., 2007;
Takahashi and Afford, 2002). Of interest, the previous results (Longhi-
Balbinot et al., 2009) and data of the present study showed that the
antinociception caused by TTHL administrated either intrathecally or
orally, besides promoting signiﬁcant antinociception, did not produce
locomotor impairment. It is important to mention that the nociceptive
response inducedby formalin and glutamate results froma combination
of peripheral input and spinal cord sensitization (Sakurada et al., 2003;
Santos and Calixto, 1997; Tjølsen et al., 1992). The i.pl. injection of
formalin and glutamate releases excitatory amino acids, PGE2, NO,
neuropeptides and kinins in the spinal cord (Beirith et al., 2002;
Sakurada et al., 2003; Tjølsen et al., 1992). Thus, the antinociceptive
effect evoked by TTHL could be dependent on either peripheral or
central sites of action. In this regard, we demonstrated that the
intrathecal (central) injection of TTHL signiﬁcantly inhibited nocicep-
tion caused by either the peripheral or spinal administration of
glutamate. Based on these data, we suggest that this effect could be by
a direct action on glutamatergic neurons located in the spinal cord
(Longhi-Balbinot et al., 2009).
Here, in order to investigate someof themechanisms underlying the
antinociceptive response produced by systemically administered TTHL,
we employed the model of nociception by glutamate because this
triterpene causes consistent antinociception with good reproducibility.
Despite of the relation between glutamate and NO cascades
(Garthwaite, 1991; Meller and Gebhart, 1993; Meller et al., 1996), the
L-arginine–NO pathway is unlikely to be involved in the antinocicep-
tive effect of TTHL. This conclusion is drawn from the fact that pre-
treatment with the substrate for NOS, L-arginine, at a dose that
produces no signiﬁcant effect on glutamate-induced nociception,
signiﬁcantly reversed the antinociception caused by L-NAME (a nitric
oxide synthase inhibitor), but did not alter the antinociceptive effect
of TTHL.It is well known that the sensation of pain ismodiﬁed by endogenous
pain inhibitory systems, such as endogenous opioids (β-endorphin and
dynorphin) and descending serotonin (5-HT). Opioid receptors are
widely distributed in several peripheral tissues (Wittert et al., 1996) and
cutaneous nerves (Ständer et al., 2002; Stein et al., 1990), as well as the
central nervous system, especially in the pain transmission pathways like
the dorsal horn of the spinal cord (Lao et al., 2008; Ninkovic et al., 1982)
and small cells in dorsal root ganglia (Botticelli et al., 1981). There are
three classical opioid receptors: μ, κ and δ. All are G protein-coupled
receptors. Theyalso signal in similarways, coupling toguaninenucleotide
binding regulatory proteins (Gi/o) to inhibit adenylyl cyclase, open inner-
rectifying K+ channels and inactivate L-type and N-type Ca2+ channels.
All three of these receptors mediate analgesia in the spinal cord (Budai
and Fields, 1998; Chen and Pan, 2006; Chen et al., 2007; Takemori and
Portoghese, 1993).
In the present study, we showed that the opioid system is involved in
the antinociceptive effect induced by TTHL. This observation is based on
the fact that naloxone, a non-selective opioid receptor antagonist, as well
as CTOP (a selective μ-opioid receptor antagonist), nor-binaltorphimine
(a selective κ-opioid receptor antagonist) and naltrindole (a selective
δ-opioid receptor antagonist) not only reversed the antinociceptive
effect of morphine (a non-selective opioid agonist, positive control),
but also reversed TTHL-induced antinociception in mice. In view of
these results, we can speculate that TTHL may elicit an antinocicep-
tive effect either by releasing endogenous opioid that can bind to
their speciﬁc opioid receptors, or by interacting with opioid
receptors. However, other studies are necessary to further substan-
tiate this assertion.
Data in the literature has demonstrated a possible interaction
between 5-HT and the opioid systems. In the CNS, serotonergic neurons
are involved in the pain inhibition induced by opioid agonists.
Furthermore, an enhanced rate of release of serotonin into perfusates
of rat spinal cord occurred when morphine was injected into
periaqueductal greymatter (Hamon et al., 1991; Fürst, 1999). Serotonin
was also observed to modulate the pain transmission in the spinal cord
and in the brain (Yaksh and Wilson, 1979). Autoradiographic studies
showed that 5-HT1A, 5-HT1B, 5-HT1D and 5-HT3 binding sites are
abundant in the spinal cord. However, their roles in the control of
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studies showing that 5-HT antagonists, i.e. 5-HT3 antagonists, can
produce both pronociceptive (Ali et al., 1996; Green et al., 2000; Oatway
et al., 2004; Suzuki et al., 2002) and antinociceptive effects (Alhaider
et al., 1991; Glaum et al., 1990; Paul et al., 2001). On the other hand,
others demonstrated that the activation of spinal cord serotonin
subtype receptors 5-HT1A and 5-HT2 produce antinociception (Bardin
et al., 2000; Millan, 2002). The data presented here suggest that the
serotonergic system could be involved in the antinociceptive effect of
TTHL in mice. This supposition is based on the fact that the depletion
of endogenous serotonin with tryptophan hydroxylase inhibitor
PCPA, aside from signiﬁcantly reversing morphine antinociception,
largely antagonized the antinociceptive action of TTHL. Furthermore,
pre-treatment of mice with selective antagonists of 5-HT1A,WAY100635,
5-HT2A, ketanserin, but not with 5-HT3 antagonist, ondansetron,
signiﬁcantly reversed the antinociception caused by systemic adminis-
tration of TTHL.
Another interesting ﬁnding demonstrated in the present study is
that inactivation of theGi/o protein through i.t. pertussis toxin treatment
reversed the antinociceptive effect induced by TTHL and morphine.
Pertussis toxin (PTX) inactivates the Gi/o by ADP-ribosylation of the α-
subunit of this protein (Wen et al., 2003), disrupting inhibitory Gi/o
protein-coupled signal transduction, and consequently, leading to a
predominance of the spinal excitatory receptor system. Additionally,
inhibitory neurotransmitter receptors (i.e., opioid and 5-HT) are linked
toPTX-sensitive proteins (AghajanianandWang, 1986; Jeongand Ikeda,
2001), and inactivation of these G-proteins may contribute to the
activation of excitatory receptors, such as the NMDA receptor (Jeong
and Ikeda, 2001). Furthermore, Ito et al. (2000) showed that activation
of 5-HT1A promotes the opening of K+ channels and closing of Ca2+
channels through coupling negatively to adenylyl cyclase, therefore
inhibiting sensory transmission. In addition, activation of Gi/o protein is
considered an inhibitory signaling event, since it inhibits adenylyl
cyclase and opens two different types of K+ inward rectiﬁer (Kir)
channels: K+-ATP dependent and G-protein-regulated inwardly recti-
fying K+ (GIRK) channels (Childers and Deadwyler, 1996; Ocaña et al.,
2004).
Corroborating these data, we demonstrated that pre-treatment
with glibenclamide, a blocker of the K+-ATP dependent channel,
charybdotoxin, a blocker of large (or fast)-conductance calcium-gated
K+ channels and tetraethylammonium, a blocker of voltage-gated K+
channels, reverse the TTHL antinociceptive effect. However, pre-
treatment with apamin, a blocker of small (or low)-conductance
calcium-gated K+ channels, did not prevent the TTHL action.
In conclusion, the present results are in agreement with previous
data and demonstrate that TTHL produces antinociception when
systemically administered. Furthermore, these evidences showed that
the TTHL-induced antinociception involves the opioidergic (i.e.,
through μ, κ and δ receptors) and serotonergic systems (i.e., through
5-HT1A and 5-HT2A receptors), Gi/o protein activation and opening of
speciﬁc K+ channels (ATP dependent, voltage- and large-conductance
Ca2+-gated). Together, the present results indicate that TTHL might
be of potential interest in the development of new clinically relevant
drugs for the management of pain. Although, additional studies are
necessary to conﬁrm this hypothesis.
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